Reactions 1704, p281 - 2 Jun 2018
Pneumonitis: 3 case reports
A study described three patients [ages and sexes not stated]
who developed pneumonitis during treatment with nivolumab
for non-small cell lung cancer. The patients started receiving
nivolumab therapy at a dose of 3 mg/kg [route not stated] and
developed moderate to severe grade pneumonitis [time to
reactions onset not stated]. The first patient was treated with
mycophenolate, prednisolone and methyprednisolone. The
second patient received prednisolone and
methylprednisolone, and the third patient received
prednisolone only. Nivolumab was discontinued for the first
two patients [outcomes not stated].
Author comment: "Immune-related adverse event such as
pneumonitis can be a major concern in patients with lung
cancer who may already have pre-morbid lung disease. This
study describes the rates and effects of immune-related
complications with nivolumab".
Samaranayake C, et al. Pneumonitis and other immune related complications from
nivolumab therapy in patient with non-small cell lung cancer: A descriptive study.
Respirology 23 (Suppl. 1): 199 abstr. 175, Mar 2018. Available from: URL: http://
doi.org/10.1111/resp.13268 [abstract] - Australia
Reactions 2 Jun 2018 No. 17040114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved